The short version of AOD9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-12 and is reviewed periodically as new material appears.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
=== Effect on nutrients and sensory quality === Due to the low processing temperatures and the minimization of deterioration reactions, nutrients are retained and color is maintained. Freeze-dried fruit maintains its original shape and has a characteristic soft crispy texture.
== History == The safety and effectiveness of eladocagene exuparvovec were demonstrated in an open-label, single-arm clinical study in 13 children with confirmed diagnosis of aromatic L-amino acid decarboxylase deficiency. At the start of the study, all participants had no gross motor function (the most severe presentation of aromatic L-amino acid decarboxylase deficiency) and decreased aromatic L-amino acid decarboxylase activity in the plasma. Participants treated with eladocagene exuparvovec were compared to untreated participants (natural history). Motor milestone assessments were completed for 12 of the 13 participants at week 48 after receiving the treatment. The efficacy of eladocagene exuparvovec was demonstrated based on gross motor function improvement in 8 of 12 treated participants, which has not been reported in untreated participants with the severe presentation of aromatic L-amino acid decarboxylase deficiency.
A formal order was given to not use the white flag so that the action would be considered a ceasefire instead of a surrender. Much of the fighting ended on May 7; however, the ceasefire was not respected on Isabelle, the isolated southern position, where the battle lasted until May 8, 1:00 am. At least 2,200 members of the 20,000-strong French forces died, and another 1,729 were reported missing after the battle, and 11,721 were captured. The Viet Minh suffered approximately 25,000 casualties over the course of the battle, with as many as 10,000 Viet Minh personnel having been killed in the battle. The French prisoners taken at Điện Biên Phủ were the greatest number the Việt Minh had ever captured: one-third of the total captured during the entire war. Dien Bien Phu was a serious defeat for the French and was the decisive battle of the Indochina war. The battle would thus heavily influence the outcome of the 1954 Geneva accords.
== Current status == Antimicrobial resistance is the driving force for the development of new antimicrobial agents. The complexity and diversity of resistance mechanisms has defined the need for new and improved β-lactam antibiotics. With their broad spectrum the cephalosporins have come to dominate β-lactam chemotherapy although they often lack oral bioavailability. On 29 October 2010, a new cephalosporin agent - Ceftarolin - was approved by the food and drug administration (FDA). Teflaro (ceftaroline fosamil) is an injectable antibiotic prodrug to treat adults with acute bacterial skin and skin structure infections (ABSSI) and community acquired bacterial pneumonia (CABP). Ceftobiprole has been approved for the treatment of adult patients with hospital acquired pneumonia (excluding VAP) and community acquired pneumonia in 12 European countries, Canada and Switzerland.
Sources: en.wikipedia.org
Delegates from the member countries attend committee and other meetings. Former Deputy Secretary-General Pierre Vinde estimated in 1997 that the cost borne by the member countries, such as sending their officials to OECD meetings and maintaining permanent delegations, is equivalent to the cost of running the secretariat. The OECD regularly holds minister-level meetings and forums as platforms for a discussion on a broad spectrum of thematic issues relevant to the OECD charter, member countries, and non-member countries.
=== Professional services === He has fulfilled roles in numerous professional organizations, including the Swedish Biochemical Society (secretary 1976–1982); Chairman of the Swedish National Committee on Biochemistry, Royal Swedish Academy of Sciences, 1988–1990; Chairman Scientific Program Committee for the 22nd Meeting of the Federation of European Biochemical Societies, FEBS 1993; editorial boards of the Biochemical Journal, ChemBioChem, Biochimica et Biophysica Acta, Protein Engineering Design and Selection, the Journal of Biological Chemistry. In addition, he has had advisory roles at various companies: Telik Inc.; PanVera Corporation, Pharmacia Biotech; Uniroyal Chemical Company; Biovitrum AB; Maxygen; Vividion; Oxford Biomedical Research, Rochester Hills, Michigan.
== Classification == The MEROPS protease classification system counts 16 superfamilies (as of 2013) each containing many families. Each superfamily uses the catalytic triad or dyad in a different protein fold and so represent convergent evolution of the catalytic mechanism. The majority belong to the S1 family of the PA clan (superfamily) of proteases. For superfamilies, P: superfamily, containing a mixture of nucleophile class families, S: purely serine proteases. superfamily. Within each superfamily, families are designated by their catalytic nucleophile, (S: serine proteases).
=== Private versus state-owned slaves === Slaves have been owned privately by individuals but have also been under state ownership. For example, the kisaeng were women from low castes in pre modern Korea, who were owned by the state under government officials known as hojang and were required to provide entertainment to the aristocracy. In the 2020s, in North Korea, Kippumjo ("Pleasure Brigades") are made up of women selected from the general population to serve as entertainers and as concubines to the rulers of North Korea. "Tribute labor" is compulsory labor for the state and has been used in various iterations such as corvée, mit'a and repartimiento. The internment camps of totalitarian regimes such as the Nazis and the Soviet Union placed increasing importance on the labor provided in those camps, leading to a growing tendency among historians to designate such systems as slavery. A combination of these include the encomienda where the Spanish Crown granted private individuals the right to the free labour of a specified number of natives in a given area. In the "Red Rubber System" of both the Congo Free State and French ruled Ubangi-Shari, labour was demanded as taxation; private companies were conceded areas within which they were allowed to use any measures to increase rubber production. Convict leasing was common in the Southern United States where the state would lease prisoners for their free labour to companies.
This was confirmed to be as effective as the antibiotic vancomycin at inhibiting Clostridioides difficile infection without having a significant effect on the overall microbial composition of the gut. Glycerol solutions have been used for the preservation and storage of tissue grafts at ambient conditions as an alternative to frozen storage. Glycerol has also been incorporated as a component of bio-ink formulations in the field of bioprinting. The glycerol content acts to add viscosity to the bio-ink without adding large protein, saccharide, or glycoprotein molecules. It is on the World Health Organization's List of Essential Medicines for its use in treating atopic eczema.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.